Operator: Thank you. One moment, please. Alright. Our next question comes from the line of Dae Gon Ha from Stifel. Please go ahead.
Dae Gon Ha: Hey, good morning guys. Thanks for taking our questions and congrats on the progress as well. Just reverting back to Derek’s question, just hitting it head on as just apologies if I’ve missed it. But the discontinuation rate, David, you had other conference recently talking about mid-single-digits. I just wanted to confirm that number is still true. And then in terms of the questions I had, one, when you think about the patient dispositions across the three dose levels that are in the label, can you comment on any kind of – I guess Jennifer kind of went into education to get patients into, sort of the more tolerant dose. But any color you can provide across the three doses? What kind of position we should be expecting going forward?
And what work is being done to keep patients off of the 1 milligram and more skewed towards the 3 milligram arm. And then secondly, on the strategies for the reimbursement, David, you spoke previously a number of times as sort of the analog we should be thinking about for BBS going forward. But just harkening back to your rare disease experience? What kind of reimbursement rate should we be expecting eventually? I mean is this something that can near into 80%, 90% or hovering in the 70% and what work needs to be done for IMCIVREE to get there? Thank you so much.
David Meeker: Thanks, Dae Gon. So, first on the discontinuation rates. We previously, as you noted, said, I would characterize, we’re drifting up a little bit there surprisingly as we get more patients on for longer periods of time, so I’d characterize this with high level single digits. But as Jennifer said and this is what’s most encouraging overall is, one, I think we’ve done much, much better than we did in clinical trials for the reasons she outlined, the close contact with the patients who are within . Second is, patients are discontinuing about half are related to side effects of the drug. Again, opportunity will just continue to educate and set expectations in the right way. And the other are personal issues, specific to that individual patient, some of which may resolve over time and patients being willing to come back on therapy and we have several of those examples.
So, including others that we’re working. Regarding dosing, the whole strategy behind seeing here is, we start low and we’re going a little slower than we did in the trial. Not surprisingly, if you go a bit more gradually, the early tolerability is better. Number 1, number 2, the vast majority of patients are getting to . I would say balance of the patient population is early and still working their way there. So, my expectation is that the truly vast majority of patients will be at or close to 3 mgs. Younger patients, very young patients may in fact achieve their desired level of benefit at a lower dose level, but go back to our Phase III trial where we had a number, about half the patients were under age of 18 and the other half were over and then on BBS, again, that was – those patients were literally virtually all on 3 mg.
